There are currently 387 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Spectrum Health - Butterworth Campus, Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
NCT04494295
Recruiting
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Supratentorial Hemorrhage
Register for Updates
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331
Recruiting
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 in participants with PSMA-positive mCRPC who have been previously treated with 177Lu-PSMA-617 or another 177Lu-PSMA radioligand therapy (RLT).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/15/2025
Locations: BAMF Health, Grand Rapids, Michigan
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Colon Cancer, Metastatic Colon Cancer
Register for Updates
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419
Recruiting
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
02/13/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Register for Updates
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/12/2025
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
STOP Persistent AF PAS
NCT05005949
Recruiting
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Spectrum Health Hospitals, Grand Rapids, Michigan
Conditions: Persistent Atrial Fibrillation
Register for Updates
QTX3046 in Patients with KRAS G12D Mutations
NCT06428500
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: South Texas Accelerated Research Therapeutics, LLC Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor
Register for Updates
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
02/05/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Severe Aplastic Anemia
Register for Updates
Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus
NCT06232304
Recruiting
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
02/05/2025
Locations: Helen Devos Children's Hospital, Grand Rapids, Michigan
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder)
Register for Updates
Prospective Case Collection Study for New Mammography Technologies
NCT05199701
Recruiting
To evaluate the safety and efficacy of the proposed investigational device and assess its clinical utility in breast cancer screening and diagnosis to support continuing technology development of the investigational technology.
Gender:
FEMALE
Ages:
Between 35 years and 100 years
Trial Updated:
02/05/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Mammography
Register for Updates
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
Recruiting
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor
Register for Updates